Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 03, 2018 16:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., July 03, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to nine new employees for an aggregate of 30,700...
June 21, 2018 09:00 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Named one of Boston Business Journal’s Best Places to Work for the Second Year in a Row

BURLINGTON, Mass., June 21, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has been named as one of the Boston Business Journal’s “Best Places to Work” for...
June 01, 2018 17:13 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to eight new employees for an aggregate of 50,000...
May 08, 2018 16:01 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Reports First-Quarter 2018 Financial Results and Recent Business Highlights

Company booked net ZILRETTA® sales of $2.2 million in Q1Positive developments in Medicare reimbursement with CMS issuing Q code for ZILRETTA (effective 7/1/18) and recommending dedicated J code...
May 07, 2018 07:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Names David Arkowitz as Chief Financial Officer

BURLINGTON, Mass., May 07, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that David Arkowitz has been named Chief Financial Officer (CFO). Mr. Arkowitz brings...
May 04, 2018 07:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Announces ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Recommended for Unique J Code by CMS

BURLINGTON, Mass., May 04, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the Centers for Medicare and Medicaid Services (CMS) has included ZILRETTA (triamcinolone...
May 03, 2018 16:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BURLINGTON, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to seven new employees for an aggregate of 38,300...
April 30, 2018 16:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Report First-Quarter 2018 Financial Results on May 8, 2018

BURLINGTON, Mass., April 30, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2018 financial results after the close of the...
April 29, 2018 09:00 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Announces Presentation of Positive FX201 Data at the Osteoarthritis Research Society International World Congress

Results from preclinical osteoarthritis (OA) models demonstrate relief of pain, functional improvement and suggest disease-modifying efficacy following a single intra-articular injection BURLINGTON,...
April 26, 2018 07:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Presents Updated Results from Clinical Trial Evaluating Repeat Administration of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) at Osteoarthritis Research Society International World Congress

Average time to second administration was more than 16 weeks74% of patients received second administration of ZILRETTA between Weeks 16 and 24Results indicate robust treatment response in a...